Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease

Journal of Bone and Mineral Metabolism

Volumn 23, Issue 1, 2005, Pages 48-52

  Kitano, Masayasu ^a   Ogata, Atsushi ^a   Sekiguchi, Masahiro ^a   Hamano, Teruaki ^a   Sano, Hajime ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Alendronate; Bisphosphonate; Multiple myeloma; Osteoclast

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM ION; COLLAGEN; INTERLEUKIN 18;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE MARROW; CALCIUM URINE LEVEL; CELL ACTIVITY; CLINICAL ARTICLE; CROSS LINKING; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; MALE; MONOCYTE; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TREATMENT OUTCOME; URINE LEVEL;

ADULT; AGED; ALENDRONATE; ANESTHETICS, INTRAVENOUS; BETA 2-MICROGLOBULIN; BONE DISEASES; CALCIUM; COLLAGEN; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; MONOCYTES; MULTIPLE MYELOMA; OSTEOCLASTS; TUMOR MARKERS, BIOLOGICAL;

EID: 12444311696     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-004-0540-0     Document Type: Article

References (28)

1. Croucher PI, Apperley JF (1988) Bone disease in multiple myeloma. Br J Haematol 103:902-910
2. Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X (2002) RANK (receptor activator of nuclear factor-kappa B) and RANKL expression in multiple myeloma. Br J Haematol 117:86-92
3. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 101:2094-2098
4. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96:671-675
5. Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD (2001) Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108:1833-1841
6. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D, Matsumoto T (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195-2202
7. Russell RGG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97-106
8. Jantunen E, Laakso M (1996) Bisphosphonates in multiple myeloma: current status; future perspectives. Br J Haematol 93:501-506
9. Belch AR, Bergasagel DE, Wilson K, Belch AR, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B (1991) Effect of daily etidronate in the osteolysis of multiple myeloma. J Clin Oncol 9:1397-1402
10. Lahtinen R, Laakson M, Palva I, Virkkunen P, Elomaa I, for the Finnish Leukemia Group (1992) Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 340: 1049-1052
11. McCloskey EV, Maclennma ICM, Dryson MT, Chapman C, Dunn J, Kans JA (1998) A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 100:317-325
12. Berenson JR, Lightenstein A, Porter L, Dipoulos MA, Bordoni R, Geore S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seman J, Knight RD, for the Myeloma Aledia Study Group (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488-493
13. Brincker H, Westin J, Abildgaard N, Gimsing P, Turesson I, Hedenus M, Ford J, Kandra A, for Danish-Swedish Co-operative Study Group (1998) Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 101:280-286
14. Menssen HD, Sakalova A, Fontana A, Herrmann Z, Boewer C, Facon T, Lichinitser MR, Singer CR, Euller-Ziegler L, Wetterwald M, Fiere D, Hrubisko M, Thiel E, Delmas PD (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20:2353-2359
15. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377-387
16. Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Dougados M, Amor B (1994) Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:41-49
17. Rodan GA, Seedor JG, Balena R (1993) Preclinical pharmacology of alendronate. Osteoporos Int 3:S7-S12
18. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842-854
19. Fujikawa Y, Quinn JM, Sabokbar A, McGee JO, Athanasou NA (1996) The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060
20. Menaa C, Kurihara N, Roodman GD (2000) CFU-GM-derived cells form osteoclasts at a very high efficiency. Biochem Biophys Res Commun 267:943-946
21. Arai F, Miyamoto T, Ohneda O, Inada T, Sudo T, Brasel K, Miyata T, Anderson DM, Suda T (1999) Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190:1741-1754
22. Katavic V, Grcevic D, Lee SK, Kalinowski J, Jastrzebski S, Dougall W, Anderson D, Puddington L, Aguila HL, Lorenzo JA (2003) The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors. Bone 32:581-590
23. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, Nabeshima Y, Nakamura K, Sinclair AM, Scheuermann RH, Kuro-o M (2001) Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167:2625-2631
24. Nutt SL, Heavey B, Rolink AG, Busslinger M (1994) Commitment to the B-lymphoid lineage depends on the transcription factor Pax5 (comment). Nature 401:556-562
25. Mahmoud MS, Huang N, Nobuyoshi M, Lisukov IA, Tanaka H, Kawano MM (1996) Altered expression of Pax-5 gene in human myeloma cells. Blood 87:4311-4315
26. Borson ND, Lacy MQ, Wettstein PJ (2002) Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 100:4629-4639
27. Udagawa N, Horwood NJ, Elliott J, Mackay A, Owens J, Okamura H, Kurimoto M, Chambers TJ, Martin TJ, Gillespie MT (1997) Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 185:1005-1012
28. Yamada N, Niwa S, Tsujimura T, Iwasaki T, Sugihara A, Futani H, Hayashi S, Okamura H, Akedo H, Terada N (2002) Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 30:901-908